Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions | Zendy

Kirsten Fischer | Zendy; Othman AlSawaf | Zendy; Jasmin Bahlo | Zendy; Anna-Maria Fink | Zendy; Maneesh Tandon | Zendy; Mark Dixon | Zendy; Sandra Robrecht | Zendy; Simon Warburton | Zendy; Kathryn Humphrey | Zendy; Olga Samoylova | Zendy; A. M. Liberati | Zendy; Javier PinillaIbarz | Zendy; Stephen Opat | Zendy; Liliya Sivcheva | Zendy; Katell Le Dû | Zendy; Laura Fogliatto | Zendy; Carsten Utoft Niemann | Zendy; Robert Weinkove | Zendy; Sue Robinson | Zendy; Thomas J. Kipps | Zendy; Sebastian Böettcher | Zendy; Eugen Tausch | Zendy; Rod Humerickhouse | Zendy; Barbara Eichhorst | Zendy; ClemensMartin Wendtner | Zendy; Anton W. Langerak | Zendy; Karl-Anton Kreuzer | Zendy; Matthias Ritgen | Zendy; Valentin Goede | Zendy; Stephan Stilgenbauer | Zendy; Mehrdad Mobasher | Zendy; Michael Hallek | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

Author(s) -

Kirsten Fischer,

Othman AlSawaf,

Jasmin Bahlo,

Anna-Maria Fink,

Maneesh Tandon,

Mark Dixon,

Sandra Robrecht,

Simon Warburton,

Kathryn Humphrey,

Olga Samoylova,

A. M. Liberati,

Javier PinillaIbarz,

Stephen Opat,

Liliya Sivcheva,

Katell Le Dû,

Laura Fogliatto,

Carsten Utoft Niemann,

Robert Weinkove,

Sue Robinson,

Thomas J. Kipps,

Sebastian Böettcher,

Eugen Tausch,

Rod Humerickhouse,

Barbara Eichhorst,

ClemensMartin Wendtner,

Anton W. Langerak,

Karl-Anton Kreuzer,

Matthias Ritgen,

Valentin Goede,

Stephan Stilgenbauer,

Mehrdad Mobasher,

Michael Hallek

Publication year - 2019

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1815281

Subject(s) - obinutuzumab , venetoclax , chlorambucil , medicine , ighv@ , regimen , hazard ratio , chronic lymphocytic leukemia , oncology , gastroenterology , surgery , confidence interval , leukemia , chemotherapy , cyclophosphamide

The BCL2 inhibitor venetoclax has shown activity in patients with chronic lymphocytic leukemia (CLL), but its efficacy in combination with other agents in patients with CLL and coexisting conditions is not known.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research